JPWO2021226553A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021226553A5 JPWO2021226553A5 JP2022567472A JP2022567472A JPWO2021226553A5 JP WO2021226553 A5 JPWO2021226553 A5 JP WO2021226553A5 JP 2022567472 A JP2022567472 A JP 2022567472A JP 2022567472 A JP2022567472 A JP 2022567472A JP WO2021226553 A5 JPWO2021226553 A5 JP WO2021226553A5
- Authority
- JP
- Japan
- Prior art keywords
- immunomodulatory protein
- seq
- fold
- amino acid
- baff
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000018102 proteins Nutrition 0.000 claims description 195
- 102000004169 proteins and genes Human genes 0.000 claims description 195
- 108090000623 proteins and genes Proteins 0.000 claims description 195
- 230000002519 immonomodulatory effect Effects 0.000 claims description 194
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 82
- 229920001184 polypeptide Polymers 0.000 claims description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 81
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 66
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 66
- 235000001014 amino acid Nutrition 0.000 claims description 60
- 230000027455 binding Effects 0.000 claims description 59
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 55
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims description 55
- 238000006467 substitution reaction Methods 0.000 claims description 54
- 102220498722 Protein LRATD2_H19Y_mutation Human genes 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 26
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 24
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 230000004936 stimulating effect Effects 0.000 claims description 20
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102220359928 c.229A>G Human genes 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 102220541232 Cystatin-D_H19R_mutation Human genes 0.000 claims description 10
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 10
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102200122316 rs121434582 Human genes 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 9
- 102220344288 rs1554032090 Human genes 0.000 claims description 9
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102220032940 rs367543239 Human genes 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 102220631244 Interferon regulatory factor 6_R84G_mutation Human genes 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 102200065463 rs1014454531 Human genes 0.000 claims description 7
- 102220595179 Casein kinase II subunit alpha'-interacting protein_F78W_mutation Human genes 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 102220359218 c.223C>G Human genes 0.000 claims description 6
- 102200144455 rs115887120 Human genes 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 230000020385 T cell costimulation Effects 0.000 claims description 5
- 230000024245 cell differentiation Effects 0.000 claims description 5
- 230000011748 cell maturation Effects 0.000 claims description 5
- 208000026872 Addison Disease Diseases 0.000 claims description 4
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 208000003435 Optic Neuritis Diseases 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 206010002022 amyloidosis Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 4
- 108091008034 costimulatory receptors Proteins 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 102200101766 rs72554324 Human genes 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 102220198315 rs1057519973 Human genes 0.000 claims description 3
- 102200143688 rs121434227 Human genes 0.000 claims description 3
- 102220010430 rs138439950 Human genes 0.000 claims description 3
- 102200035693 rs140005285 Human genes 0.000 claims description 3
- 102220286033 rs1553301271 Human genes 0.000 claims description 3
- 102200135024 rs35877720 Human genes 0.000 claims description 3
- 102200101764 rs72554320 Human genes 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 claims description 2
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102220237632 rs1554721897 Human genes 0.000 claims description 2
- 102200118207 rs33936967 Human genes 0.000 claims description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 16
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 16
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 16
- 102220349821 c.106A>T Human genes 0.000 claims 12
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 8
- 102200016464 rs104894278 Human genes 0.000 claims 6
- 102220085035 rs552361923 Human genes 0.000 claims 6
- 102220192411 rs749977756 Human genes 0.000 claims 6
- 102220240040 rs375440229 Human genes 0.000 claims 5
- 102220229766 rs762461044 Human genes 0.000 claims 5
- 102220060529 rs774330292 Human genes 0.000 claims 5
- 102220503783 Cytotoxic T-lymphocyte protein 4_V45D_mutation Human genes 0.000 claims 4
- 102220032306 rs104895313 Human genes 0.000 claims 4
- 102220286690 rs1554306525 Human genes 0.000 claims 4
- 102220323918 rs1555018337 Human genes 0.000 claims 4
- 102200136369 rs17843776 Human genes 0.000 claims 4
- 102220024604 rs267607644 Human genes 0.000 claims 4
- 101001110988 Homo sapiens 60S ribosomal protein L35a Proteins 0.000 claims 3
- 102220484417 Myb/SANT-like DNA-binding domain-containing protein 1_Q25K_mutation Human genes 0.000 claims 3
- 102220483691 Myb/SANT-like DNA-binding domain-containing protein 1_Q25L_mutation Human genes 0.000 claims 3
- 102220593541 PMS1 protein homolog 1_N11D_mutation Human genes 0.000 claims 3
- 102220537687 Partner and localizer of BRCA2_L35A_mutation Human genes 0.000 claims 3
- 102200108123 rs104894540 Human genes 0.000 claims 3
- 102200114568 rs281875284 Human genes 0.000 claims 3
- 102200082873 rs33946157 Human genes 0.000 claims 3
- 102220060528 rs768676557 Human genes 0.000 claims 3
- 102220188872 rs886053704 Human genes 0.000 claims 3
- 102220601065 Armadillo repeat-containing protein 5_F14Y_mutation Human genes 0.000 claims 2
- 102220529810 Homer protein homolog 3_A43S_mutation Human genes 0.000 claims 2
- 102220614767 Ras-related protein Rab-3B_T36N_mutation Human genes 0.000 claims 2
- 102220609526 Sodium-dependent neutral amino acid transporter B(0)AT1_Q25V_mutation Human genes 0.000 claims 2
- 102100040092 X-linked retinitis pigmentosa GTPase regulator Human genes 0.000 claims 2
- 102220362350 c.28C>G Human genes 0.000 claims 2
- 102200033384 rs104893954 Human genes 0.000 claims 2
- 102220223286 rs1060501211 Human genes 0.000 claims 2
- 102200094174 rs121918193 Human genes 0.000 claims 2
- 102220138536 rs146905561 Human genes 0.000 claims 2
- 102200074510 rs2015352 Human genes 0.000 claims 2
- 102220144360 rs201940585 Human genes 0.000 claims 2
- 102200019491 rs267608260 Human genes 0.000 claims 2
- 102200082894 rs334 Human genes 0.000 claims 2
- 102200028671 rs3765620 Human genes 0.000 claims 2
- 102200099204 rs4280262 Human genes 0.000 claims 2
- 102220062536 rs555329870 Human genes 0.000 claims 2
- 102200131342 rs56694480 Human genes 0.000 claims 2
- 102220065694 rs569851503 Human genes 0.000 claims 2
- 102200067010 rs587621539 Human genes 0.000 claims 2
- 102220166735 rs61747004 Human genes 0.000 claims 2
- 102220183537 rs760971365 Human genes 0.000 claims 2
- 102220292977 rs769123303 Human genes 0.000 claims 2
- 102220122118 rs774714794 Human genes 0.000 claims 2
- 102220072339 rs794728992 Human genes 0.000 claims 2
- 102200140028 rs79555199 Human genes 0.000 claims 2
- 102220083144 rs863224688 Human genes 0.000 claims 2
- 102220130334 rs886045568 Human genes 0.000 claims 2
- 102220496562 Aryl hydrocarbon receptor nuclear translocator-like protein 1_H19C_mutation Human genes 0.000 claims 1
- 102220498717 Protein LRATD2_H19A_mutation Human genes 0.000 claims 1
- 102220498718 Protein LRATD2_H19Q_mutation Human genes 0.000 claims 1
- 102220465563 Putative uncharacterized protein OBSCN-AS1_H19P_mutation Human genes 0.000 claims 1
- 102220470411 Thymosin beta-4_S16A_mutation Human genes 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 102220159921 rs1057515669 Human genes 0.000 claims 1
- 102220244944 rs770609243 Human genes 0.000 claims 1
- 102220155715 rs886062788 Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 16
- 239000000710 homodimer Substances 0.000 description 15
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102200025123 rs145047094 Human genes 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010036073 Polyglandular autoimmune syndrome type II Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102200113220 rs35220041 Human genes 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022373P | 2020-05-08 | 2020-05-08 | |
| US63/022,373 | 2020-05-08 | ||
| US202063034361P | 2020-06-03 | 2020-06-03 | |
| US63/034,361 | 2020-06-03 | ||
| US202063080643P | 2020-09-18 | 2020-09-18 | |
| US63/080,643 | 2020-09-18 | ||
| PCT/US2021/031432 WO2021226553A2 (en) | 2020-05-08 | 2021-05-07 | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023525032A JP2023525032A (ja) | 2023-06-14 |
| JP2023525032A5 JP2023525032A5 (https=) | 2024-05-16 |
| JPWO2021226553A5 true JPWO2021226553A5 (https=) | 2024-05-16 |
Family
ID=76270049
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567473A Active JP7748393B2 (ja) | 2020-05-08 | 2021-05-07 | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| JP2022567472A Pending JP2023525032A (ja) | 2020-05-08 | 2021-05-07 | Ｔ細胞阻害タンパク質を伴うおよび伴わない、ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| JP2025103686A Pending JP2025134866A (ja) | 2020-05-08 | 2025-06-19 | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567473A Active JP7748393B2 (ja) | 2020-05-08 | 2021-05-07 | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025103686A Pending JP2025134866A (ja) | 2020-05-08 | 2025-06-19 | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US20230241168A1 (https=) |
| EP (2) | EP4146683B1 (https=) |
| JP (3) | JP7748393B2 (https=) |
| KR (2) | KR20230029621A (https=) |
| CN (5) | CN117736297A (https=) |
| AU (3) | AU2021268033A1 (https=) |
| BR (2) | BR112022022433A2 (https=) |
| CA (2) | CA3178882A1 (https=) |
| CL (1) | CL2022003104A1 (https=) |
| CO (1) | CO2022017780A2 (https=) |
| DK (1) | DK4146683T3 (https=) |
| FI (1) | FI4146683T3 (https=) |
| HR (1) | HRP20260229T1 (https=) |
| IL (2) | IL297981A (https=) |
| MX (2) | MX2022013999A (https=) |
| PE (1) | PE20230494A1 (https=) |
| RS (1) | RS67815B1 (https=) |
| TW (1) | TW202208414A (https=) |
| WO (2) | WO2021226551A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| KR20220034742A (ko) * | 2019-12-24 | 2022-03-18 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질 및 그 용도 |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| JP2024514077A (ja) * | 2021-03-31 | 2024-03-28 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用 |
| KR20240019124A (ko) * | 2021-05-07 | 2024-02-14 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법 |
| AU2022327178A1 (en) * | 2021-08-11 | 2024-03-28 | Akso Biopharmaceutical, Inc. | METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF |
| JP2024538452A (ja) * | 2021-11-17 | 2024-10-21 | オーリニア・ファーマシューティカルズ・インコーポレイテッド | Ｂ細胞活性化因子（ｂａｆｆ）－増殖誘導リガンド（ａｐｒｉｌ）二重阻害剤 |
| IL317055A (en) * | 2022-06-08 | 2025-01-01 | Remegen Co Ltd | METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN |
| WO2024044721A1 (en) * | 2022-08-25 | 2024-02-29 | University Of Washington | Injectable recombinant protein-based hydrogels for therapeutic delivery |
| JP2025532251A (ja) * | 2022-09-30 | 2025-09-29 | レメゲン シーオー．，エルティーディー． | ＴＡＣＩ－Ｆｃ融合タンパク質を用いた膜性腎症の治療方法 |
| WO2024077018A2 (en) * | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
| KR20250116728A (ko) * | 2022-12-05 | 2025-08-01 | 알렉시온 파마슈티칼스, 인코포레이티드 | Baff, april, 및 신생아 fc 수용체의 다기능적 억제를 위한 taci-fc 융합 단백질 |
| EP4527375A1 (en) * | 2022-12-07 | 2025-03-26 | RemeGen Co., Ltd. | Taci-fc fusion protein liquid pharmaceutical preparation |
| WO2025007943A1 (zh) * | 2023-07-06 | 2025-01-09 | 荣昌生物制药(烟台)股份有限公司 | 用taci-fc融合蛋白治疗anca相关性血管炎的方法 |
| WO2025240392A1 (en) * | 2024-05-13 | 2025-11-20 | Paragon Therapeutics, Inc. | Fusion proteins |
| WO2026008004A1 (zh) * | 2024-07-04 | 2026-01-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法 |
Family Cites Families (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| DK0584266T3 (da) | 1991-05-06 | 2003-12-29 | Us Gov Health & Human Serv | Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| JP4418965B2 (ja) | 1994-09-23 | 2010-02-24 | タップイミューン・インコーポレイテッド | 内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法 |
| JP3907698B2 (ja) | 1994-10-03 | 2007-04-18 | アメリカ合衆国 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ES2248823T5 (es) | 1996-10-25 | 2011-11-03 | Human Genome Sciences, Inc. | Neutroquina alfa. |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| DK2272859T3 (en) | 1998-08-07 | 2015-01-19 | Univ Washington | Immunological herpes simplex virus antigens and methods for their use |
| US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
| DE60043626D1 (de) | 1999-01-07 | 2010-02-11 | Zymogenetics Inc | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 |
| US7833529B1 (en) * | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
| PT1916258E (pt) | 1999-08-09 | 2014-07-29 | Genzyme Corp | Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| CA2396793A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US20040013674A1 (en) | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
| JP2004513876A (ja) | 2000-04-27 | 2004-05-13 | バイオジェン インコーポレーテッド | 抗−腫瘍剤としてのｔａｃｉ |
| EP1746106A3 (en) | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Use of TACI as an anti-tumor agent |
| US20020086018A1 (en) | 2000-05-12 | 2002-07-04 | Theill Lars Eyde | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
| CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| CA2411828A1 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| JP2004537290A (ja) | 2001-05-24 | 2004-12-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体 |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| BR0211614A (pt) | 2001-08-03 | 2006-10-31 | Genentech Inc | polipeptìdeo tacis e br3 e empregos dos mesmos |
| EP1456347A4 (en) | 2001-11-16 | 2006-08-02 | Human Genome Sciences Inc | IMMUNE SPECIFIC TO BLYS BINDING ANTIBODIES |
| US7247615B2 (en) | 2001-11-30 | 2007-07-24 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen and uses therefor |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| CN1692127A (zh) | 2002-07-25 | 2005-11-02 | 健泰科生物技术公司 | Taci抗体及其用途 |
| EP1558278B1 (en) | 2002-10-11 | 2009-09-02 | ZymoGenetics, Inc. | Production of homotrimeric fusion proteins |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AU2003299971A1 (en) | 2002-12-30 | 2004-07-29 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| PL1631313T3 (pl) | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
| AU2004285455A1 (en) | 2003-10-20 | 2005-05-12 | Biogen Idec Ma Inc. | Therapeutic regimens for BAFF antagonists |
| KR100956913B1 (ko) | 2003-12-19 | 2010-05-11 | 제넨테크, 인크. | 치료제로서 유용한 일가 항체 단편 |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| CA2585927A1 (en) | 2004-11-04 | 2006-05-18 | Genentech, Inc. | Polypeptides that bind baff and/or april |
| WO2006060314A2 (en) | 2004-12-01 | 2006-06-08 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1922079A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| AU2006278229B2 (en) | 2005-08-09 | 2011-10-27 | Ares Trading S.A. | Methods for treating B-cell malignancies using TACI-Ig fusion molecule |
| WO2007019618A1 (en) | 2005-08-12 | 2007-02-22 | Garvan Institute Of Medical Research | Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
| JP2007103345A (ja) | 2005-09-07 | 2007-04-19 | Toyota Motor Corp | チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法 |
| ES2415890T3 (es) | 2005-09-09 | 2013-07-29 | Zymogenetics, Inc. | Procedimiento de preparación de proteínas triméricas |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EA015860B1 (ru) | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| US8202698B2 (en) | 2005-11-08 | 2012-06-19 | Biogen Idec Ma Inc. | Methods of evaluating BAFF |
| JP2009537563A (ja) | 2006-05-15 | 2009-10-29 | アレス トレーディング ソシエテ アノニム | Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法 |
| BRPI0714495B8 (pt) | 2006-07-21 | 2021-05-25 | California Inst Of Techn | lentivírus deficiente para replicação recombinante pseudotipado |
| JP2010501622A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ−融合タンパク質の精製法 |
| EA017733B1 (ru) | 2006-08-28 | 2013-02-28 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ |
| DK2061803T4 (da) | 2006-08-28 | 2022-12-05 | Ares Trading Sa | Fremgangsmåde til oprensning af fc-holdige proteiner |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| CA2674213A1 (en) | 2007-01-26 | 2008-07-31 | Merck Serono S.A. | Purification of fc-taci fusion proteins using the oilbody technology |
| JP5426531B2 (ja) | 2007-03-27 | 2014-02-26 | ザイモジェネティクス， インコーポレイテッド | 自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ |
| SG182191A1 (en) | 2007-06-13 | 2012-07-30 | Zymogenetics Inc | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
| CN101323643B (zh) | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| EP2170946A2 (en) | 2007-07-13 | 2010-04-07 | The Johns Hopkins University | B7-dc variants |
| EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| CA2701221A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an fc-containing protein |
| WO2009062960A1 (en) | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Formulations for taci-immunoglobulin fusion proteins |
| JP2011503036A (ja) | 2007-11-12 | 2011-01-27 | アレス トレーディング ソシエテ アノニム | 再発性多発性硬化症治療のためのｔａｃｉ−免疫グロブリン融合タンパク質 |
| WO2009062916A1 (en) | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
| WO2009132058A2 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
| AU2009241442B2 (en) | 2008-05-01 | 2014-11-27 | Zymogenetics, Inc. | Levels of BLyS/ APRIL heterotrimers in serum and use in diagnostic methods |
| EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010093993A2 (en) | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| EP2435477A1 (en) | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| CN101851278B (zh) | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
| US20110311548A1 (en) | 2010-06-18 | 2011-12-22 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system |
| US20130295672A1 (en) | 2010-09-10 | 2013-11-07 | Consejo Superior De Investigaciones Científicas | Stem cell culture media and methods |
| CN102085368B (zh) | 2011-01-19 | 2013-06-12 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| RS55609B1 (sr) | 2011-04-13 | 2017-06-30 | Bristol Myers Squibb Co | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| CN102585016B (zh) * | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| PT2831095T (pt) | 2012-03-30 | 2019-01-30 | Immune Design Corp | Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign |
| MX2014014951A (es) | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
| CN103232542B (zh) * | 2013-02-01 | 2015-05-13 | 殷勇 | 一种双靶标嵌合蛋白 |
| EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| ES2870802T3 (es) | 2013-02-12 | 2021-10-27 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| HK1219740A1 (zh) | 2013-03-15 | 2017-04-13 | Biogen Ma Inc. | 使用抗αVβ5抗体治疗和预防急性肾损伤 |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| US10562954B2 (en) * | 2014-05-12 | 2020-02-18 | Shanghai Kanda Biotechnology Co., Ltd. | Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof |
| WO2015181343A2 (en) | 2014-05-30 | 2015-12-03 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
| EP3169352A1 (en) | 2014-07-15 | 2017-05-24 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| EP3322801A1 (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| DK3380522T5 (da) | 2015-11-25 | 2024-09-30 | Visterra Inc | Antistofmolekyler til april og anvendelser deraf |
| US10954301B2 (en) * | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| EP4706777A2 (en) | 2016-04-15 | 2026-03-11 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| IL262365B2 (en) | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| US20200326339A1 (en) | 2016-05-16 | 2020-10-15 | James Richard BERENSON | Improved methods for monitoring immune status of a subject |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CA3040296A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| PT3596116T (pt) | 2017-03-16 | 2023-12-04 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de pd-l1 variante e suas utilizações |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| EP3642243A4 (en) | 2017-06-20 | 2021-04-28 | Dana-Farber Cancer Institute, Inc. | METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION |
| CN111655280B (zh) | 2017-09-01 | 2025-01-14 | 达纳-法伯癌症研究所股份有限公司 | 用于治疗癌症的bcma和taci抗原特异的免疫原性肽 |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SMT202600062T1 (it) | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| GB201720426D0 (en) | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| US20210238295A1 (en) | 2018-04-26 | 2021-08-05 | University Of Virginia Patent Foundation | Compositions and methods for treating abdominal aortic aneurysm |
| CN110522908A (zh) | 2018-05-25 | 2019-12-03 | 荣昌生物制药（烟台）有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| WO2020028572A2 (en) | 2018-08-01 | 2020-02-06 | Unum Therapeutics Inc. | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
| WO2020047329A1 (en) | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
| AU2019345151B2 (en) | 2018-09-19 | 2025-04-17 | Alpine Immune Sciences, Inc. | Methods and uses of variant CD80 fusion proteins and related constructs |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| EP4438054A3 (en) | 2019-04-17 | 2025-01-08 | Alpine Immune Sciences, Inc. | Methods and uses of variant icos ligand (icosl) fusion proteins |
| CN114728040A (zh) | 2019-06-14 | 2022-07-08 | 科优基因公司 | 新型白介素-2变体及其双功能融合分子 |
| EP4056232A4 (en) | 2019-09-13 | 2023-09-13 | Kyowa Kirin Co., Ltd. | DCR3 VARIANT |
| AU2020401160B2 (en) | 2019-12-10 | 2024-11-14 | Remegen Co., Ltd. | Pharmaceutical TACI-Fc fusion protein formulation |
| KR20220034742A (ko) | 2019-12-24 | 2022-03-18 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질 및 그 용도 |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| AU2021285813A1 (en) | 2020-06-02 | 2023-02-02 | Ares Trading S.A. | Methods related to the treatment of IGA nephropathy |
| KR20240019124A (ko) | 2021-05-07 | 2024-02-14 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법 |
| US20240002468A1 (en) | 2021-08-10 | 2024-01-04 | Remegen Co., Ltd. | Method for treating iga nephropathy with taci-fc fusion protein |
| AU2022358137B2 (en) | 2021-09-30 | 2026-02-12 | Remegen Co., Ltd. | Method for treating sjogren’s syndrome using taci-fc fusion protein |
| IL317055A (en) | 2022-06-08 | 2025-01-01 | Remegen Co Ltd | METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN |
| WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
-
2021
- 2021-05-07 JP JP2022567473A patent/JP7748393B2/ja active Active
- 2021-05-07 AU AU2021268033A patent/AU2021268033A1/en active Pending
- 2021-05-07 BR BR112022022433A patent/BR112022022433A2/pt unknown
- 2021-05-07 EP EP21730003.7A patent/EP4146683B1/en active Active
- 2021-05-07 HR HRP20260229TT patent/HRP20260229T1/hr unknown
- 2021-05-07 CN CN202311249622.3A patent/CN117736297A/zh active Pending
- 2021-05-07 KR KR1020227043139A patent/KR20230029621A/ko active Pending
- 2021-05-07 WO PCT/US2021/031430 patent/WO2021226551A1/en not_active Ceased
- 2021-05-07 MX MX2022013999A patent/MX2022013999A/es unknown
- 2021-05-07 IL IL297981A patent/IL297981A/en unknown
- 2021-05-07 FI FIEP21730003.7T patent/FI4146683T3/fi active
- 2021-05-07 CA CA3178882A patent/CA3178882A1/en active Pending
- 2021-05-07 CA CA3178885A patent/CA3178885A1/en active Pending
- 2021-05-07 US US17/923,208 patent/US20230241168A1/en active Pending
- 2021-05-07 RS RS20260260A patent/RS67815B1/sr unknown
- 2021-05-07 AU AU2021267276A patent/AU2021267276B2/en active Active
- 2021-05-07 TW TW110116616A patent/TW202208414A/zh unknown
- 2021-05-07 IL IL297980A patent/IL297980A/en unknown
- 2021-05-07 BR BR112022022524A patent/BR112022022524A2/pt unknown
- 2021-05-07 DK DK21730003.7T patent/DK4146683T3/da active
- 2021-05-07 MX MX2022013998A patent/MX2022013998A/es unknown
- 2021-05-07 CN CN202180047833.1A patent/CN115812077A/zh active Pending
- 2021-05-07 US US17/315,168 patent/US12202882B2/en active Active
- 2021-05-07 CN CN202411219401.6A patent/CN119258195A/zh active Pending
- 2021-05-07 CN CN202180047593.5A patent/CN116194467A/zh active Pending
- 2021-05-07 CN CN202310582491.4A patent/CN116903727A/zh active Pending
- 2021-05-07 WO PCT/US2021/031432 patent/WO2021226553A2/en not_active Ceased
- 2021-05-07 EP EP21730004.5A patent/EP4146684A2/en active Pending
- 2021-05-07 JP JP2022567472A patent/JP2023525032A/ja active Pending
- 2021-05-07 PE PE2022002607A patent/PE20230494A1/es unknown
- 2021-05-07 KR KR1020227043140A patent/KR20230029622A/ko active Pending
- 2021-06-11 US US17/346,095 patent/US11274140B2/en active Active
-
2022
- 2022-11-08 CL CL2022003104A patent/CL2022003104A1/es unknown
- 2022-12-07 CO CONC2022/0017780A patent/CO2022017780A2/es unknown
-
2024
- 2024-08-16 US US18/807,825 patent/US12304943B2/en active Active
- 2024-09-24 US US18/895,259 patent/US20250019413A1/en active Pending
- 2024-09-24 US US18/895,187 patent/US20250019412A1/en active Pending
-
2025
- 2025-01-22 AU AU2025200430A patent/AU2025200430A1/en active Pending
- 2025-06-19 JP JP2025103686A patent/JP2025134866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021226553A5 (https=) | ||
| EP1362062B1 (en) | Concatameric immunoadhesion | |
| JP4741464B2 (ja) | 改良したＦｃ融合タンパク質 | |
| EP2344540B1 (en) | Cd86 antagonist multi-target binding proteins | |
| AU2002313952A1 (en) | Concatameric immunoadhesion | |
| JP2025134866A5 (https=) | ||
| FI4146683T3 (fi) | Aprilia ja baffia estäviä immunomoduloivia proteiineja ja niiden käyttömenetelmiä | |
| US20030187224A1 (en) | Chimeric OPG polypeptides | |
| US20100249381A1 (en) | Method for Purifying FC-Fusion Proteins | |
| JP2004528014A5 (https=) | ||
| JP2019512222A (ja) | Ｔ細胞調節多量体ポリペプチド及びその使用方法 | |
| WO2018199595A1 (ko) | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 | |
| JPWO2021226551A5 (https=) | ||
| CA3136816A1 (en) | Methods and uses of variant icos ligand (icosl) fusion proteins | |
| WO1995006737A1 (en) | Glycophorin binding protein (gbp130) fusion compositions | |
| JP2010512154A (ja) | 修飾Ｆｃドメインを含む多量体Ｆｃ受容体ポリペプチド | |
| Ashkenazi et al. | Immunoadhesins: an alternative to human monoclonal antibodies | |
| WO2022251552A2 (en) | Antigen presenting polypeptide complexes and methods of use thereof | |
| KR100418329B1 (ko) | 직렬 연쇄체를 갖는 면역접합체 | |
| US20240252601A1 (en) | Ace2 fusion proteins and uses thereof | |
| CN116621989A (zh) | 一种多聚化结构单体及其用途 | |
| HK1062305B (en) | Concatameric immunoadhesion |